What should the practicing physician know about digoxin bioavailability and how will FDA action affect him?

A. Gilman, R. M. Harvey, T. Killip

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Original language	English
Pages (from-to)	399-400
Number of pages	2
Journal	Circulation
Volume	49
Issue number	3
DOIs	https://doi.org/10.1161/01.cir.49.3.399
State	Published - 1974
Externally published	Yes

Access to Document

10.1161/01.cir.49.3.399

Cite this

@article{1b2614d7055948c7860a5b318a7fffcb,

title = "What should the practicing physician know about digoxin bioavailability and how will FDA action affect him?",

author = "A. Gilman and Harvey, \{R. M.\} and T. Killip",

year = "1974",

doi = "10.1161/01.cir.49.3.399",

language = "English",

volume = "49",

pages = "399--400",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - What should the practicing physician know about digoxin bioavailability and how will FDA action affect him?

AU - Gilman, A.

AU - Harvey, R. M.

AU - Killip, T.

PY - 1974

Y1 - 1974

UR - https://www.scopus.com/pages/publications/0016040190

U2 - 10.1161/01.cir.49.3.399

DO - 10.1161/01.cir.49.3.399

M3 - Article

C2 - 4813171

AN - SCOPUS:0016040190

SN - 0009-7322

VL - 49

SP - 399

EP - 400

JO - Circulation

JF - Circulation

IS - 3

ER -